µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis

Inclusion Criteria: * Women * Age ≥ 60 years * Bone mineral density T-score of either the spine (L1-L4), total hip or femoral neck of ≤ - 2.0, or has a history of an osteoporotic fracture Exclusion Criteria: * Previous treatment with pamidronate, ibandronate, of more than 2 doses in 2 years and of zoledronic acid at any time * Previous treatment with teriparatide, alendronate or risedronate of more than 2 months in the last 24 months * Previous treatment with calcitonin within the previous year; previous treatment with an estrogen or selective estrogen modulator will not exclude a potential subject unless she has been taking it for \< 1 year (a woman who discontinued estrogen or a selective estrogen receptor within the previous year will also be excluded) * Other diseases known to affect bone, such as Paget's disease, Cushing's disease, hyperthyroidism, hyperparathyroidism, bone cancer and metastases to bone, and vitamin D deficiency * Medications known to affect bone, such as anticonvulsants, high dose glucocorticoids (20 mg/day or more \> 2 weeks within the previous 6 months) * Current alcohol use \> 3 drinks/day * Untreated or unstable cardiac, pulmonary, liver (SGOT \> 2X upper limit of normal) or renal disease (creatinine \> 1.2 mg/dL) or uncontrolled diabetes (hemoglobin A1C \> 8.0) * Prior radiation therapy to the skeleton * Cardiac pacemakers, ferromagnetic implants or brain aneurysm clips * Claustrophobia * Subjects whose initial MRI is of poor quality due to motion artifact will be asked to repeat the examination; if a repeat MRI is of poor quality due to motion artifact, the subject will be excluded from the study * Abnormalities of the which delay esophageal emptying such as stricture or achalasia * Inability to stand or sit upright for at least 30 minutes * Hypocalcemia * Uric acid level \>7.5ml/dl * Subjects with metallic objects in their bodies